Benjamin Gregory Carlisle
Benjamin Gregory Carlisle
Verified email at - Homepage
Cited by
Cited by
Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials
B Carlisle, J Kimmelman, T Ramsay, N MacKinnon
Clinical trials 12 (1), 77-83, 2015
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib
B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review
J Mattina, B Carlisle, Y Hachem, D Fergusson, J Kimmelman
PLoS biology 15 (2), e2000487, 2017
Rethinking Research Ethics: The Case of Postmarketing Trials
AJ London, J Kimmelman, B Carlisle
Science 336 (6081), 544-545, 2012
Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
A Hakala, J Kimmelman, B Carlisle, G Freeman, D Fergusson
BMJ 350, 2015
Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval
B Carlisle, CA Federico, J Kimmelman
Bmj 360, 2018
Drug development at the portfolio level is important for policy, care decisions and human protections
J Kimmelman, B Carlisle, M Gönen
Jama 318 (11), 1003-1004, 2017
Proof of prespecified endpoints in medical research with the bitcoin blockchain
BG Carlisle
The Grey Literature 25, 2014
Imatinib and the long tail of targeted drug development
BG Carlisle, T Zheng, J Kimmelman
Nature Reviews Clinical Oncology 17 (1), 1-3, 2020
Clinical trials stopped by Covid-19
BG Carlisle
Open Science, 2020
Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs
CA Federico, B Carlisle, J Kimmelman, DA Fergusson
British journal of pharmacology 171 (18), 4247-4254, 2014
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
BG Carlisle, A Doussau, J Kimmelman
BMJ open 10 (2), e034306, 2020
Numbat meta-analysis extraction manager
BG Carlisle
Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers
M Salholz-Hillel, D Strech, BG Carlisle
Clinical Trials 19 (3), 337-346, 2022
Patient participation in clinical trials of oncology drugs and biologics preceding approval by the US Food and Drug Administration
N Hutchinson, B Carlisle, A Doussau, R Bosan, E Gumnit, A MacPherson, ...
JAMA network open 4 (5), e2110456-e2110456, 2021
Impact of precision medicine on efficiencies of novel drug development in cancer
H Sarvas, B Carlisle, S Dolter, E Vinarov, J Kimmelman
JNCI: Journal of the National Cancer Institute 112 (8), 859-862, 2020
Benefit, burden, and impact for a cohort of post-approval cancer combination trials
BG Carlisle, A Doussau, J Kimmelman
Clinical Trials 17 (1), 18-29, 2020
Analysis of clinical trial registry entry histories using the novel R package cthist
BG Carlisle
Plos one 17 (7), e0270909, 2022
How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials. gov
N Hutchinson, K Klas, BG Carlisle, J Kimmelman, M Waligora
Plos one 17 (1), e0262114, 2022
How well are phase 2 cancer trial publications supported by preclinical efficacy evidence?
M Pratte, S Ganeshamoorthy, B Carlisle, J Kimmelman
International Journal of Cancer 145 (12), 3370-3375, 2019
The system can't perform the operation now. Try again later.
Articles 1–20